Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18556937 | 0.86 | ELANE (0.71) | ELANEPRTN3 | |
| SCHEMBL17356345 | 0.84 | ELANE (0.69) | ELANEPRTN3 | |
| SCHEMBL10483720 | 0.83 | ELANE (1.00) | ELANEPRTN3 | |
| SCHEMBL22369614 | 0.82 | ELANE (0.86) | ELANEPRTN3 | |
| SCHEMBL21538650 | 0.82 | ELANE (0.89) | ELANEPRTN3 | |
| SCHEMBL3657615 | 0.81 | ELANE (0.76) | ELANEPRTN3 | |
| SCHEMBL16189796 | 0.81 | ELANE (0.76) | ELANEPRTN3 | |
| SCHEMBL3657617 | 0.81 | ELANE (0.76) | ELANEPRTN3 | |
| SCHEMBL4029716 | 0.81 | ELANE (0.65) | ELANEPRTN3 | |
| SCHEMBL17151769 | 0.81 | ELANE (0.65) | ELANEPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076476-B2 | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits | AVI BIOPHARMA, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2207779-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | Avi Biopharma, Inc. (US) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009064471-A1 | METHOD OF SYNTHESIS OF MORPHOLINO OLIGOMERS | AVI BIOPHARMA, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | AVI BIOPHARMA, INC. (US) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131624-A1 | SYNTHESIS OF MORPHOLINO OLIGOMERS USING DOUBLY PROTECTED GUANINE MORPHOLINO SUBUNITS | RNMT, O60361, PAM | ELANE 4358/4885PRTN3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.